AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00845026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 10 mg dose (2-5 mg oral tablets) once every evening, for 3 days. Followed by an increase to 15 mg (3-5 mg oral tablets) once every evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10 mg or a maximum of 20 mg (4-5 mg oral tablets).
Study NCT00845026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: 2 mg dose, 2-1 mg oral tablets, given once or twice a day for 3 days. Followed by an increase to 4 mg (4-1 mg tablets), given once or twice a day, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 2 mg/day or a maximum of 6 mg/day (6-1 mg tablets).
Study NCT04692220 — intervention group
Intervention type: OTHER
Intervention: Detection of Adverse Drug Events or Drug-Related Problems
Description: Detection of Adverse Drug Events or Drug-Related Problems
Study NCT00323674 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polysoft Mesh
Description: Polysoft Mesh is used.
Study NCT00323674 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light Weight Mesh
Description: Light Weight Mesh is used.
Study NCT00971204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioFocus HeartLight Endoscopic Ablation System
Description: PVI ablation
Study NCT03844568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nocturnal nasal continuous positive airway pressure
Description: applying nasal continuous positive airway pressure at 7.5-10cmH2O for at least 4 hours during nighttime
Study NCT01190306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The VEGA UV-A Illumination System
Description: This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
Study NCT01190306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: Riboflavin is a solution that will be delivered to the treatment area
Study NCT01190306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Riboflavin is a solution that will be delivered to the treatment area
Study NCT03817632 — intervention group
Intervention type: DEVICE
Intervention: Computer assisted primary total knee replacement with OrthoPilot FS101 navigation system and Software 5.1
Description: Computer Assisted Total Knee Replacement with the OrthoPilot FS101 and the software TKA 5.1
Study NCT03817632 — intervention group
Intervention type: DEVICE
Intervention: Computer assisted primary total knee replacement with OrthoPilot Elite navigation system and Software 6.0
Description: Computer Assisted Total Knee Replacement with the with the OrthoPilot Elite and the software TKA 6.0
Study NCT02784860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the lidocaine group, lidocaine 2% is administered as a bolus followed by a continuous intravenous infusion after loss of consciousness
Study NCT02784860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the placebo group, the same volume of normal saline is administered after loss of consciousness
Study NCT02174900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine
Study NCT02174900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine
Study NCT02174900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-Lumefantrine (AL) combination
Study NCT02174900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine
Study NCT02174900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine
Study NCT03337737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Extreme Endurance
Description: Study will compare (in a crossover) placebo vs dietary supplement Extreme Endurance.
Study NCT03337737 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03598452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: Intravitreal Injection of Ganciclovir (IVG) was conducted in a week interval. The initial dose was 6mg/0.1ml at the first injection and it was reduced to 4.5mg/0.1ml at the second time; 3mg/0.1ml of IVG was maintained until the CMV could not be detected in aqueous humor.
Study NCT02542150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetate
Description: acetate infusion, saline infusion, functional magnetic resonance imaging (fMRI) scan
Study NCT02542150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alcohol
Description: a jello shot containing alcohol, a jello shot containing no alcohol, fMRI scan.
Study NCT00652379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegvisomant
Description: Pegvisomant s.c 15-30 mg 2 times a week
Study NCT00652379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin analog (lanreotide or octreotide)
Description: Study arm 2: usual dosage of a somatostatin analog Study arm 1: half dosage of somatostatin analog
Study NCT00652379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin analog (lanreotide or octreotide)
Description: Study arm 2: usual dosage of a somatostatin analog Study arm 1: half dosage of somatostatin analog
Study NCT06191510 — intervention group
Intervention type: PROCEDURE
Intervention: Bio-Oss Exposed
Description: Molar extraction with a flapless approach and immediate implant installation, filling the gap with deproteinized bovine bone mineral (Geistlich Bio-Oss) and left exposed to the oral environment.
Study NCT06191510 — intervention group
Intervention type: PROCEDURE
Intervention: Mucograft Exposed
Description: Molar extraction with a flapless approach and immediate implant installation, filling the gap with deproteinized bovine bone mineral (Bio-Oss; Geistlich) and covered by a collagen matrix (Mucograft; Geistlich).
Study NCT04839237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards,1.8mg per day, subcutaneous injection.
Study NCT04839237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide;metformin
Description: The treatment of Liraglutide combined with metformin lasted three months.For Liraglutide,during the first week: 0.6mg per day, subcutaneous injection;during the second week: 1.2mg per day, subcutaneous injection; from third week onwards,1.8mg per day, subcutaneous injection.For metformin,during three months:0.5g each time, 3 times per day,oral.
Study NCT03493854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin 60 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of either ddAC Q2W or AC Q3W) for Cycles 1-4.
Study NCT03493854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 60 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of either ddAC Q2W or AC Q3W) for Cycles 1-4.
Study NCT03493854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: As part of one of the two investigator's choices of chemotherapy (AC followed by docetaxel), docetaxel 75 mg/m2 will be administered IV on Day 1 of Cycle 5 and then 100 mg/m2 IV at the discretion of the investigator for Cycles 6-8 (Q3W), if no dose-limiting toxicity occurs.
Study NCT03493854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: As part of one of the two investigator's choices of chemotherapy (AC followed by docetaxel), docetaxel 75 mg/m2 will be administered IV on Day 1 of Cycle 5 and then 100 mg/m2 IV at the discretion of the investigator for Cycles 6-8 (Q3W), if no dose-limiting toxicity occurs.
Study NCT03493854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: As part of one of the two investigator's choices of chemotherapy (ddAC followed by paclitaxel), paclitaxel 80 mg/m2 will be administered IV QW for 12 weeks.
Study NCT03005379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Therapy (FMT)
Description: Oral capsule-delivered FMT
Study NCT03005379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule-delivered placebo
Study NCT01968681 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alexandrite laser
Description: 3 different alexandrite laser settings are used in respectively 3 different treatment areas and compared with a non-treated control area.
Study NCT01052805 — intervention group
Intervention type: PROCEDURE
Intervention: harvest nerve
Description: harvest nerve from cadaveric donor and patients receiving nerve graft operation
Study NCT01222871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Triamcinolone soaked nasopore dressing
Study NCT03493854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: As part of one of the two investigator's choices of chemotherapy (ddAC followed by paclitaxel), paclitaxel 80 mg/m2 will be administered IV QW for 12 weeks.
Study NCT01222871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline soaked sponge
Description: saline soaked sponge
Study NCT03530033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Local injection of lidocaine reduces muscle tremor
Study NCT03493854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab IV
Description: Pertuzumab will be administered as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose Q3W.
Study NCT03493854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC of Pertuzumab and Trastuzumab SC
Description: The FDC of pertuzumab and trastuzumab will be administered SC at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab Q3W.
Study NCT03493854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab IV
Description: Trastuzumab will be administered as an 8-mg/kg IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
Study NCT03493854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab SC
Description: After surgery (from Cycle 9 onwards), participants in Arm A will be allowed to switch from trastuzumab IV to trastuzumab SC, at the discretion of the investigator, in the countries where trastuzumab SC is routinely used. For participants who switch, a fixed dose of 600 mg trastuzumab SC (irrespective of the patient's weight) will be administered in the adjuvant phase.
Study NCT03493854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.
Study NCT03493854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.
Study NCT03493854 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative Radiotherapy
Description: If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).
Study NCT03493854 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-operative Radiotherapy
Description: If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).
Study NCT03493854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormone Therapy
Description: For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
Study NCT03493854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone Therapy
Description: For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
Study NCT04606212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: administration of losartan (50 mg) (oral)
Study NCT04606212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: administration of placebo (oral)
Study NCT03555890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine IRT 5 mg
Description: Levocetirizine IRT will be available as film-coated tablets. Subjects will receive a single dose of 5 mg levocetirizine IRT. Subjects will receive levocetirizine IRT with 150 mL water in both Part (1 and 2).
Study NCT00396656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: 100 mg tablets orally once a day (od) in the morning.
Study NCT00396656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ))
Description: 12.5 or 25 mg tablets orally once a day (od) in the morning.
Study NCT00396656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 80 mg, 160 mg, or 320 mg tablets orally once a day in the morning
Study NCT04122417 — intervention group
Intervention type: OTHER
Intervention: The Effect Of Therapeutic Touch Training Given To Mothers With Preterm Babies On Attachment Level And The Responses The Baby
Description: The study was carried out as randomized experiment to determine the effect of Yakson or Gentle Human Touch method practiced by mothers to preterm newborns on the maternal attachment level and the baby's responses.
Study NCT02821026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omental Islet transplant
Description: The intervention is transplanting the islets into an omental pouch instead of into the liver. The omentum is a large apron-like fold of membrane inside the abdomen that drapes over the intestines. This study will test to see if omental islet transplantation is safe and effective. Standard immunosuppressive medicines (anti-thymocyte globulin, tacrolimus, mycophenolic acid, sirolimus, etanercept) will be used in this study to prevent rejection of the islets.
Study NCT02821026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Study NCT02821026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Study NCT02821026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study NCT02821026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Study NCT02821026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus will be used in case of tacrolimus or/and mycophenolate mofetil intolerance.
Study NCT01836731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classic Intervention
Description: The standard classic approach will implement a total of 20 community health club sessions delivered through weekly education programs in the target communities as per the training manual. Community health workers (CHW) will receive careful training in the delivery of the CBEHPP instruction. High quality instructional materials (in color) will be used. Club members will each receive a membership card to be used to track attendance and compliance. Finally model home competitions and a graduation ceremony will be held. Monitoring of the clubs will be conducted by community health workers using mobile phones.
Study NCT01836731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimum Intervention
Description: The lite trial arm will only implement 8 sessions covering all the WASH topics. It will be facilitated by CHWs receiving minimal training and using black/white photocopies of instructional materials. Members will not be issued with membership cards and will not have a graduation ceremony or home garden competitions. Minimal monitoring of this arm will be carried out by environmental health officers.
Study NCT02095548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690, 0.03mg/2mL
Study NCT02095548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690, 0.07mg/2mL
Study NCT02095548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690, 0.23mg/2mL
Study NCT02095548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02547220 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cinryze®
Description: Participants will receive 5000 Units of CINRYZE (50 millilitre \[mL\] of CINRYZE/ 50 mL of normal saline) on Day 1 and 2500 Units of CINRYZE (25 mL of CINRYZE/ 75 mL of normal saline) on Day 3, 5, 7, 9, 11, and 13 respectively.
Study NCT02547220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 7 doses of matched placebo over 13 days of treatment.
Study NCT02551562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NuDerm® System
Description: The Nu-Derm® System (Valeant Pharmaceuticals North America, LLP) is a skin care system that helps correct and reduce visible signs of aging such as age spots, rough skin, erythema, sallowness, and hyperpigmentation.
Study NCT02551562 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Basic skin care regimen
Study NCT00869622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: 35 mgs/week + calcium and vit d
Study NCT00869622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Calcium and Vitamin D
Description: sugar pill + calcium 1200mgs/day and vitamin d at least 800IU
Study NCT03721796 — intervention group
Intervention type: OTHER
Intervention: Audio recording of initial consultation and debriefing interviews.
Description: Semi-structured debriefing interviews with participating oncologists and HIV-infected newly diagnosed cancer patients will follow the initial encounter. Interviews will be conducted over 45-60 minutes and will be semi-structured with open-ended questions to allow the interviewee to direct the flow of the conversation.
Study NCT00552643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suspension of polystyrene beads (POLYHEAL 1)
Description: Topical application of Polyheal 1 (15 mL/200cm2 of wound area, TID, 28 days, one cycle
Study NCT00552643 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Saline (0.9% NaCl)
Description: Saline topical application 15 mL/200cm2 of wound area, TID, 28 days, one cycle
Study NCT02455206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity counseling
Description: 5 face-to-face sessions a 30 minutes during 12 weeks pulmonary rehabilitation program.
Study NCT02455206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study NCT00937365 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
Study NCT00937365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
Study NCT00937365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuroemotional Technique (NET)
Description: Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
Study NCT02528877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic bone marrow transplant
Study NCT02528877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic hematopoeitic stem cell transplant
Study NCT02528877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT02528877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02528877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV